Accelerating Parkinson’s drug development: The International Linked Clinical Trials initiative

In 2012, Cure Parkinson’s joined forces with Van Andel Institute (VAI) to hold the first international Linked Clinical Trials (iLCT) meeting in Grand Rapids, Michigan. The Committee has since met annually to evaluate and prioritise drugs for clinical trial in Parkinson’s, a review of which has now been published in the Journal of Parkinson’s Disease.


Press release

Press Release: Fundraiser of the Year 2023

11 April 2024 We are thrilled to announce that we have two winners of our 2023 Fundraiser of the Year Award: Antony Rose and Michelle Gillies! These two incredible supporters went ‘above and beyond’ to support our vital research by spending 2023 raising funds and…


News Fundraising news

Fundraiser of the Year Award 2023

We are thrilled to announce that we have two winners of our 2023 Fundraiser of the Year Award: Antony Rose and Michelle Gillies! These two incredible supporters went ‘above and beyond’ to support our vital research by spending 2023 raising funds and awareness in their…


Research events

2024 Planning for Prevention of Parkinson’s Conference

The 2024 Planning for Prevention of Parkinson’s: A Trial Design Forum conference will be held from May 5-7 in Boston, Massachusetts, US, this conference is intended to bring together Parkinson’s research stakeholders, academics, and patient advocates to share information on and inform future Parkinson’s prevention trials.


Phase 2 trial results of lixisenatide published

The full results of the one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide have now been published. This Cure Parkinson’s co-funded trial has reported positive results, indicating that the treatment may slow the progression of motor symptoms. Researchers have reported that the…